453 related articles for article (PubMed ID: 34168407)
41. The role of microbiota in hepatic encephalopathy.
Bajaj JS
Gut Microbes; 2014; 5(3):397-403. PubMed ID: 24690956
[TBL] [Abstract][Full Text] [Related]
42. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
[TBL] [Abstract][Full Text] [Related]
43. Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.
Badal BD; Bajaj JS
Med Clin North Am; 2023 May; 107(3):517-531. PubMed ID: 37001951
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
45. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM
Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740
[TBL] [Abstract][Full Text] [Related]
46. Minimal hepatic encephalopathy.
Stewart CA; Smith GE
Nat Clin Pract Gastroenterol Hepatol; 2007 Dec; 4(12):677-85. PubMed ID: 18043677
[TBL] [Abstract][Full Text] [Related]
47. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
[TBL] [Abstract][Full Text] [Related]
48. Minimal Hepatic Encephalopathy.
Redfield R; Latt N; Munoz SJ
Clin Liver Dis; 2024 May; 28(2):237-252. PubMed ID: 38548436
[TBL] [Abstract][Full Text] [Related]
49. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC; Sarin SK
Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Cai XJ; Wang L; Hu CM
J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
[TBL] [Abstract][Full Text] [Related]
51. Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients.
Fiorillo A; Gallego JJ; Casanova-Ferrer F; Urios A; Ballester MP; San Miguel T; Megías J; Kosenko E; Tosca J; Rios MP; Escudero-García D; Montoliu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834174
[TBL] [Abstract][Full Text] [Related]
52. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
Tapper EB; Essien UR; Zhao Z; Ufere NN; Parikh ND
J Hepatol; 2022 Aug; 77(2):377-382. PubMed ID: 35367057
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
[TBL] [Abstract][Full Text] [Related]
55. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
56. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Agrawal A; Sharma BC; Sharma P; Sarin SK
Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
[TBL] [Abstract][Full Text] [Related]
57. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Alsahhar JS; Rahimi RS
Curr Opin Gastroenterol; 2019 May; 35(3):145-154. PubMed ID: 30893082
[TBL] [Abstract][Full Text] [Related]
58. [Clinical importance and diagnostic methods of minimal hepatic encephalopathy].
Stawicka A; Zbrzeźniak J; Świderska A; Kilisińska N; Świderska M; Jaroszewicz J; Flisiak R
Pol Merkur Lekarski; 2016 Feb; 40(236):117-21. PubMed ID: 27000818
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: A systematic review and meta-analysis.
Wibawa IDN; Mariadi IK; Shalim CP; Sindhughosa DA
Clin Exp Hepatol; 2023 Jun; 9(2):146-153. PubMed ID: 37502435
[TBL] [Abstract][Full Text] [Related]
60. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
